NCT06343805 - A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

October 15, 2026

Study Completion Date

February 15, 2027

Conditions

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisPMFPPV-MFPET-MF

Interventions

DRUG

AJ1-11095

Type II JAK2 Inhibitor

Trial Locations (12)

10021

RECRUITING

David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

28204

RECRUITING

Levine Cancer Institute, Charlotte

33612

RECRUITING

Moffitt Cancer Cancer Center, Tampa

43210

RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

45221

RECRUITING

University of Cincinnati, Cincinnati

63110

RECRUITING

Washington University School of Medicine, St Louis

66160

RECRUITING

University of Kansas Medical Center, Kansas City

77030

RECRUITING

MD Anderson Cancer Center, Houston

94304

RECRUITING

Stanford Cancer Institute, Palo Alto

02114

RECRUITING

Massachusetts General Hospital, Boston

02115

RECRUITING

Dana Farber Cancer Institute, Boston